BiotechTube
Enara Bio

Enara Bio

Oxford, United Kingdom· Est.
enarabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Enara Bio is an emerging private biotech founded in 2019, leveraging its proprietary EDAPT® and EnTiCE® platforms to discover novel Dark Antigens and develop bispecific T-cell engagers for solid tumors. The company has secured backing from prominent investors and a strategic collaboration with Boehringer Ingelheim, validating its approach. Its lead program, ENA101, is in late preclinical development, with plans to enter First-in-Human studies, positioning it as a potential first-in-class therapy.

Oncology

Technology Platform

EDAPT® platform for discovering novel 'Dark Antigen' targets from non-coding genomic regions. EnTiCE® platform for engineering and optimizing proprietary bispecific T-cell engagers (TCEs) for solid tumors.

Opportunities

Dark Antigens offer a vast, untapped reservoir of highly cancer-specific targets, potentially enabling therapies for broad patient populations with high unmet need in solid tumors.
The successful partnership with Boehringer Ingelheim validates the platform and provides non-dilutive funding for discovery.
The bispecific TCE modality has a proven regulatory pathway, and a first-in-class candidate like ENA101 could capture significant market share if clinically successful.

Risk Factors

The novel Dark Antigen biology is unproven in humans, carrying high clinical risk for safety and efficacy.
The company is pre-revenue and dependent on raising capital, with its valuation tied to high-risk preclinical/early clinical data.
The competitive landscape for solid tumor bispecifics is intensifying rapidly, requiring clear differentiation.

Competitive Landscape

Enara Bio competes in the crowded bispecific T-cell engager and novel cancer antigen discovery spaces. Key competitors include large pharma (e.g., Roche, Amgen) and biotechs developing TCEs against known targets (e.g., EGFR, PSMA). Its primary differentiation is its focus on novel Dark Antigens from non-coding DNA, a approach also explored by companies like ROME Therapeutics and Myst Therapeutics, making technological validation critical.

More companies in Immunotherapy / Immuno-Oncology →More companies in United Kingdom →